Status:
COMPLETED
Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema
Lead Sponsor:
Minia University
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
Phase:
NA
Brief Summary
The aim of this study is To compare the anatomical and functional results of intravitreal( IV) injection of ranibizumab with sub threshold micropulse laser ( SML) in treatment of Diabetic macular edem...
Detailed Description
Diabetic macular edema (DME) causes significant visual loss in diabetic patients. About 20% and 40% of patients with Type 1 and Type 2 diabetes mellitus (DM), respectively, develop DME. One-third of d...
Eligibility Criteria
Inclusion
- DME with BCVA\<0.5 decimal Snellen acuity.
- Controlled blood glucose (HbA1c) \<6.5%.
Exclusion
- History of previous intraocular surgery,
- History of previous laser treatment,
- History of previous IV injection,
- Macular disease or ischemia,
- Proliferative diabetic retinopathy,
- Vitreoretinal traction,
- Interruption of external limiting membrane (ELM) or ellipsoid zone (EZ).
- Dense media opacity,
- Optic disc pathology
- History of strokes or ischaemic heart diseases.
- patients with (CST) \> 400 µm on OCT .
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04332133
Start Date
December 1 2016
End Date
December 1 2019
Last Update
April 3 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.